Mutations of various types are rare events that occur in all proliferating cell populations. Those affecting the germ line may be expressed by progenyY; those affecting somatic cells are more occult and therefore have received relatively little attention. Some of the first evidence that mutation occurs in mammalian somatic cells was cytogenetic: occasional cells dividing in vitro exhibits chromosome aberrations, some of which are heritable. Certain rare cancer-predisposing human genetic disorders have been discovered in which microscopically detectable aberrations are increased, Bloom's syndrome (BS) being the prototype. The types of aberrations in BS resemble those in normal cells, except for their increased frequency Cytogenetics has provided only the broadest suggestion of the nature of the mutations that occur spontaneously in proliferating somatic cells. The work proposed applies recombinant DNA technology to analyze these mutations, including those resulting from recombinational events, and to a certain extent to define them. BS cells will be used as the experimental model because of the increased frequency of mutations, as shown cytogenetically. DNA of single cells (i.e., of clones and subclones) of lymphoblastoid cells will be analyzed using a panel of molecular probes for highly polymorphic loci distributed throughout the genome that are heterozygous in the genome of the individual from whom the cultured cells had been derived. Loss of heterozygosity and the appearance of new alleles will signal the generation of DNA-base-sequence alterations. The observations will be complementary to those being made by others identifying the molecular changes present in human cancers, the hypothesis being that some type(s) of mutations occurring in diploid, non-neoplastic BS cells and in normal cells at a much lower frequency are the changes that constitute the first step in neoplastic transformation.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
1R01CA050897-01
Application #
3195509
Study Section
Mammalian Genetics Study Section (MGN)
Project Start
1989-04-01
Project End
1992-03-31
Budget Start
1989-04-01
Budget End
1990-03-31
Support Year
1
Fiscal Year
1989
Total Cost
Indirect Cost
Name
New York Blood Center
Department
Type
DUNS #
City
New York
State
NY
Country
United States
Zip Code
10065
German, James; Sanz, Maureen M; Ciocci, Susan et al. (2007) Syndrome-causing mutations of the BLM gene in persons in the Bloom's Syndrome Registry. Hum Mutat 28:743-53
Ellis, N A; Ciocci, S; German, J (2001) Back mutation can produce phenotype reversion in Bloom syndrome somatic cells. Hum Genet 108:167-73
van Brabant, A J; Ye, T; Sanz, M et al. (2000) Binding and melting of D-loops by the Bloom syndrome helicase. Biochemistry 39:14617-25
Sanz, M M; Proytcheva, M; Ellis, N A et al. (2000) BLM, the Bloom's syndrome protein, varies during the cell cycle in its amount, distribution, and co-localization with other nuclear proteins. Cytogenet Cell Genet 91:217-23
Yankiwski, V; Marciniak, R A; Guarente, L et al. (2000) Nuclear structure in normal and Bloom syndrome cells. Proc Natl Acad Sci U S A 97:5214-9
Ellis, N A; Proytcheva, M; Sanz, M M et al. (1999) Transfection of BLM into cultured bloom syndrome cells reduces the sister-chromatid exchange rate toward normal. Am J Hum Genet 65:1368-74
Neff, N F; Ellis, N A; Ye, T Z et al. (1999) The DNA helicase activity of BLM is necessary for the correction of the genomic instability of bloom syndrome cells. Mol Biol Cell 10:665-76
Walpita, D; Plug, A W; Neff, N F et al. (1999) Bloom's syndrome protein, BLM, colocalizes with replication protein A in meiotic prophase nuclei of mammalian spermatocytes. Proc Natl Acad Sci U S A 96:5622-7
Li, L; Eng, C; Desnick, R J et al. (1998) Carrier frequency of the Bloom syndrome blmAsh mutation in the Ashkenazi Jewish population. Mol Genet Metab 64:286-90
Sack, S Z; Liu, Y; German, J et al. (1998) Somatic hypermutation of immunoglobulin genes is independent of the Bloom's syndrome DNA helicase. Clin Exp Immunol 112:248-54

Showing the most recent 10 out of 24 publications